Category: News

IRVINE, Calif., Sept. 28, 2021 — Reneo Pharmaceuticals, Inc. (NASDAQ: RPHM), a clinical stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare, genetic, mitochondrial diseases, today announced that management will host a key opinion leader (KOL) webinar on McArdle Disease and other genetic mitochondrial myopathies on Monday, October 4,… Continue reading Reneo Pharmaceuticals Hosting Key Opinion Leader Webinar on McArdle Disease and other Genetic Mitochondrial Myopathies

IRVINE, Calif., Sept. 09, 2021 — Reneo Pharmaceuticals, Inc. (NASDAQ: RPHM), a clinical stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare, genetic, mitochondrial diseases, today announced that management will be participating in five investor conferences during the month of September. Details for the upcoming conferences are as follows:… Continue reading Reneo Pharmaceuticals to Participate in Upcoming Investor Conferences

First patient dosed in STRIDE study of REN001 in primary mitochondrial myopathies IRVINE, Calif., Aug. 11, 2021 — Reneo Pharmaceuticals, Inc. (Nasdaq: RPHM), a clinical stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare genetic, mitochondrial diseases, today reported financial results for the quarter ended June 30, 2021 and… Continue reading Reneo Pharmaceuticals Reports Second Quarter 2021 Financial Results

IRVINE, Calif., July 28, 2021 — Reneo Pharmaceuticals, Inc. (NASDAQ: RPHM), a clinical stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases, today announced that the first patient has been dosed in the STRIDE study. The trial is designed to evaluate the efficacy and safety of… Continue reading Reneo Pharmaceuticals Announces First Patient Dosed in the STRIDE Study

SAN DIEGO, July 09, 2021 — Reneo Pharmaceuticals, Inc. (Nasdaq: RPHM), a clinical stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases, announced today that Jefferies LLC, SVB Leerink LLC and Piper Sandler, as the representatives of the several underwriters of Reneo’s initial public offering, have… Continue reading Reneo Pharmaceuticals Announces Partial Waiver of Lock-Up Restriction

SAN DIEGO, July 07, 2021 — Reneo Pharmaceuticals, Inc. (NASDAQ: RPHM), a clinical stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare, genetic, mitochondrial diseases, today announced that it will provide a corporate update and participate in one-on-one investor meetings at the Ladenburg Thalmann 2021 Healthcare Conference, to be… Continue reading Reneo Pharmaceuticals to Present at the Ladenburg Thalmann 2021 Healthcare Conference

SAN DIEGO, June 29, 2021 — Reneo Pharmaceuticals, Inc. (NASDAQ: RPHM), a clinical stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases, joined the broad-market Russell 3000 Index at the conclusion of the 2021 Russell indexes annual reconstitution, effective after the close of the markets on… Continue reading Reneo Pharmaceuticals Added to the Russell 2000® and Russell 3000® Indices

SAN DIEGO, May 20, 2021 — Reneo Pharmaceuticals, Inc. (NASDAQ: RPHM), a clinical stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare genetic, mitochondrial diseases, today reported financial results for the quarter ended March 31, 2021 and provided an update on its clinical programs. Key Operational Highlights Initiated the… Continue reading Reneo Pharmaceuticals Reports First Quarter 2021 Financial Results

SAN DIEGO, May 19, 2021 — Reneo Pharmaceuticals, Inc. (NASDAQ: RPHM), a clinical stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare, genetic, mitochondrial diseases, today announced that it will present and participate in one-on-one investor meetings at the upcoming Jefferies Virtual Healthcare Conference taking place June 1-4, 2021.… Continue reading Reneo Pharmaceuticals to Present at the Jefferies Virtual Healthcare Conference

SAN DIEGO, April 08, 2021 — Reneo Pharmaceuticals, Inc., a clinical stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare, genetic, mitochondrial diseases, today announced the pricing of its initial public offering of 6,250,000 shares of its common stock at a public offering price of $15.00 per share, for… Continue reading Reneo Pharmaceuticals Announces Pricing of Initial Public Offering